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Introduction
Currently pancreaticoduodenectomy (PD) is the
treatment of choice for tumours of the periampullary
region. PD is a complex, high-risk surgical procedure,
considered to be one of the most binding operations 
or, maybe, the most binding  in abdominal surgery
[14].
In 1979 Moossa defined PD as ‘the Cadillac of
abdominal surgery’ [5]. In the same period the
in-hospital mortality rate after PD was 2030% with
an extremely high morbidity; severe, life-threatening
complications were judged to be a part of the
procedure [6,7].
Nowadays PD is a routine procedure in specialized
high-volume centres and mortality has decreased
significantly in the last two decades. Many efforts
have been made to gain better results; they must be
identified in preoperative and postoperative manage-
ment and appropriate selection of patients, improved
surgical skills, and development of multidisciplinary
teams dedicated to the care of pancreatic patients
[8,9]. However, even if mortality is less than 35% in
experienced hands, the overall morbidity rate is still
high  from 30% to 50%  leading to prolonged in-
hospital stay and increased costs [161].
Anastomotic leakage and the subsequent pancreatic
fistula (PF) are the most important complications
after PD. The pancreatic leakage is considered to be
the underlying phenomenon of other major complica-
tions; the anastomotic dehiscence with autodigestion
and destruction of surrounding tissue and vessels
from leaking activated pancreatic juice can
cause peripancreatic collections, intra-abdominal
abscess, delayed gastric emptying and postoperative
haemorrhage.
The reported rate of PF is highly variable, ranging
from 2% to 50% [161]. This wide range is due to
several factors and, among these, the lack of a
universally accepted definition of PF [1012].
The aim of this paper is to review the causes, risk
factors, definitions, prevention and treatment of
anastomotic leakage in pancreatic surgery, with parti-
cular regard to leakage of the pancreatico-enteric
anastomosis after PD.
Pathophysiology and risk factors
The most important pathophysiological factor in-
volved in the development of a pancreatic fistula is
the pancreatic juice itself. In fact it is rich in proteases
that, whenever activated, determine the digestion and
the destruction of the tissue leading to partial or
complete anastomotic dehiscence. In addition, pan-
creatic juice, through the fistulization of pancreatico-
enteric anastomosis can cause inflammation and auto-
destruction of the peripancreatic and retroperitoneal
tissues as well as the surrounding vessels and viscera,
with possible dramatic vascular erosions. These phe-
nomena can lead to haemorrhage, intra-abdominal
abscess, peripancreatic and retroperitoneal collections
and delayed gastric emptying which is, in most cases,
an indirect sign of intra-abdominal complications.
The presence of an intra-abdominal abscess is
strongly associated with the presence of a leak from
the pancreatic anastomosis: at least 5060% of
abscesses observed following PD are related to
pancreatic leakage [1318]. All these complications
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may be associated with sepsis, shock, single or multi-
organ failure and death [1,38,1618,6264]
The two most important risk factors for PF forma-
tion are the presence of a soft texture within the
pancreatic remnant and a small and ‘deep’ Wirsung
duct, which complicates the achievement of a safe
pancreatico-enteric anastomosis [10,13,15,19,
6466]. This is a frequent event in cases of non-
obstructive neoplasms such as tumours of the duode-
num, common bile duct, endocrine neoplasms, pa-
pilla of Vater and small ductal cancers. On the other
hand, the occurrence of a pancreatic leak among
patients who underwent PD for chronic and/or
obstructive pancreatitis is uncommon, due to fibrotic
pancreatic parenchyma, Wirsung duct dilatation and
reduced digestive secretions [19,20,6569]. Some
authors have reported an incidence of pancreatic
fistula between 12% and 36% in patients with normal
pancreatic texture compared with an incidence ran-
ging from 0% to 9% in patients with fibrotic pancreas
[16,70].
The presence of a high-tension anastomosis
and poor blood supply are other ‘surgical factors’
associated with an increased risk of leakage
[14,19,20,7073]. Moreover reoperation, emer-
gency surgery, jaundice, renal failure, cirrosis and
preoperative undernutrition are known to be
associated with higher risk of PF development
[19,63,7375].
Surgeons and hospitals: new risk factors?
Today many authors support the concept that among
the most important factors affecting the rate of
pancreatic anastomotic leak are the surgeon’s and
centre’s experience [1,3,813,15,76]. The preopera-
tive selection, the intraoperative skill and, above all,
the postoperative care of patients undergoing pan-
creatic resection, are best achieved by a multidisci-
plinary team including surgeons, radiologists,
anaesthesiologists, gastroenterologists and a specia-
lized nursing team. A reduction and a better manage-
ment of complications should be expected if
operations are concentrated in few high-volume
centres where a restricted number of well-trained
surgeons can achieve large experience standardizing
the surgical technique [21,22,7682]. Many authors
demonstrated a progressive reduction in mortality and
morbidity rates after PD in experienced centres. The
first one was J.M. Howard who reported (in 1968!) a
series of 41 PD without mortality [83]. More recently
Trede et al. and Cameron et al. reported large series
of PD without mortality [1,23]; nowadays in specia-
lized hospitals the mortality rate after major pancrea-
tic resection is B/5%. Cameron et al. defined high-
volume hospitals as those performing at least 20 PD
per year for 6 consecutive years [24]. Many elegant
studies have shown that centralization to high-volume
specialized hospitals has led to a significant lower
mortality for PD compared with the low-volume
centres [1,3,8,1215,2124,7683]. Many surgeons
can perform PD from a technical point of view but
only a few can achieve the optimal experience to
manage safely  in a multidisciplinary setting  the
major complications related to pancreatic resection.
Management of the pancreatic remnant
As mortality and morbidity following PD are strictly
related to the breakdown of the pancreatic anasto-
mosis, great concern has always been given to the
management of the pancreatic remnant and different
surgical techniques have been proposed for gastro-
intestinal continuity reconstruction, up to total pan-
createctomy to avoid the anastomosis [2550,8488].
Two general rules seem to be popular (not
evidenced-based!) among pancreatic surgeons: (1) it
is important to mobilize the pancreatic remnant from
the surrounding retroperitoneum to reduce the anasto-
motic tension; (2) blood supply at the cut surface of the
pancreas should be evaluated, and if deemed inade-
quate, the pancreas can be cut back 12 cm more.
After the original description of PD the pancreatic
stump was mainly managed by pancreatico-jejunal
anastomosis [2528,30]. Many alternatives have been
introduced to improve the results: invaginating end-
to-end or end-to-side pancreaticojejunostomy with a
one- or two-layer suture, duct-to-mucosa anastomosis
(with or without internal or external stenting of the
duct), simple suture legation of the pancreatic duct
without enteric anastomosis and ‘glue occlusion’ of
the duct [3145]. The simple suture ligation of the
duct without enteric anastomosis proved to be a high-
risk procedure, with anastomotic fistulas occurring in
50100% of the patients [30,43]. Also regarding the
occlusion of the main pancreatic duct with fibrin glue,
its use has now been abandoned on the basis of
different randomized controlled trials [3840,45].
In conclusion, even if few randomized controlled
trials are available, none of the different surgical
techniques used to perform a pancreaticojejunostomy
showed better results when compared with each other.
Another option is represented by the pancreatico-
gastrostomy [84,85]. Table I shows the different
Table I. Technical advantages of the pancreogastric anastomosis
after PD.
/ The stomach and the pancreas are closed, facilitating a
tension-free anastomosis.
/ The stomach wall has a good blood supply, enhancing
anastomotic healing.
/ In the absence of enterokinase activity and thanks to the
gastric acid pH, pancreatic enzymes are not activated, thus
reducing the risk of leakage.
/ The pancreatic anastomosis can be controlled in the
postoperative course through endoscopy, possible
anastomotic bleeding can be treated easily.
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theoretical advantages of pancreaticogastric anasto-
mosis [4650,85,86].
Yeo et al., in the first prospective randomized trial
comparing pancreaticogastrostomy and pancreatico-
jejunostomy after PD, demonstrated a similar pan-
creatic leak rates in the two groups [46]. Recently, at
our institution we carried out a prospective rando-
mized study comparing these two reconstructive
techniques in a homogenous population of patients
and we found a lower rate of biliary fistula, abdominal
collections and delayed gastric emptying in the
pancreaticogastrostomy group, but not a significant
difference in the incidence of pancreatic leak [48].
In general, a drain is placed near the pancreatic
anastomosis. The drain must not directly touch the
anastomosis, as theoretically this can make it easier for
an anastomotic leakage to develop. For the same
reason the drain should not left inside for a longer
time than needed but should be removed, whenever
possible, in a few days. At the same time, when the
complication develops, thanks to the ‘well left’ drain
the fistula can be completely drained and an operative
reintervention avoided . . . The problem of the ‘drain
management’ is still open. It is interesting to under-
line that Conlon et al. in a prospective randomized
trial did not find differences in terms of morbidity
when comparing patients with versus patients without
drains [87,88].
At the moment there is no definite evidence that
any particular reconstructive surgical technique is
safer and associated with better results than any of
the others. Moreover, there have been few prospective
trials and the lack of a universally accepted definition
of PF makes it difficult to evaluate the different results
achieved objectively.
Octreotide in the prevention of pancreatic
leakage
As postoperative complications after PD are mainly
caused by the action of enzymes, the pharmacological
inhibition of pancreatic exocrine secretion in the
perioperative period can be of help in the prevention
of pancreatic leakage. Octreotide is a long-acting
somatostatin analogue which can significantly reduce
pancreatic and gastric as well as enteric secretions
[89,90]. For this reason octreotide has been used as
prophylactic agent for anastomotic leak after elective
pancreatic head resection [91]. One experimental
study demonstrated that somatostatin treatment in
patients who undergo PD results in a significant
reduction of postoperative drainage volume as well
as serum levels of amylase and lipase [92].
In different studies octreotide has been adminis-
tered preoperatively, intraoperatively and postopera-
tively and its potential benefit has been evaluated in
several randomized controlled trials with controversial
results. Recently Connor et al. [51], in a meta-analysis
of 10 well-selected randomized clinical trials [5261]
with a total of 1918 patients (Table II), demonstrated
that somatostatin and its analogues (octreotide) did
not reduce the mortality rate after pancreatic surgery
but did reduce both the total morbidity (p/0.002)
and pancreas-specific complications (p/0.003).
Moreover somatostatin and octreotide can reduce
the rate of biochemical fistula formation but not the
incidence of clinical anastomotic disruption. The
absolute difference in the number of complications
suggestive of an anastomotic leak for all the included
trials between patients treated with octreotide/
somatostatin and those in the control group was
11% (37% versus 26%, respectively). Thus nine
patients required to be treated with these drugs to
prevent one pancreas-specific complication.
However, while octreotide is widely used in Europe,
many American surgeons remain unconvinced regard-
ing a real advantage from using octreotide, believing
that a reduction in postoperative pancreatic leakage
depends mainly on other factors, such as the centra-
lization of pancreatic patients in high-volume centres
[56,57,59].
Rosenburg et al. showed that the use of octreotide is
a cost-effective strategy in patients undergoing elective
pancreatic surgery, able to reduce the hospitalization
of these patients and its related costs. This economic
evaluation estimated that the routine use of octreotide
would prevent 16 patients from developing complica-
tions per 100 patients treated and would save $1642
per patient [93].
Multicentre prospective randomized controlled
trials are needed in this area, with clearly defined
criteria on indications, dose and timing of adminis-
tration to assess the potential advantage of octreotide
use. Moreover any future attempt to identify sub-
groups of patients who are most likely to benefit from
these drugs will require standardization of definitions,
surgical techniques and risk stratification.
The problem of the definition
The lack of a single, objective, universally accepted
definition of PF makes it difficult to compare different
surgical techniques and the usefulness of prophylactic
drugs in pancreatic surgery [1113].
In particular, many studies involving pancreatic
surgery defined a leak by the volume of drain output
and/or drain fluid amylase concentration. However,
there is a considerable variation in fluid volume,
amylase content, values and timing of test adminis-
tration between different studies. In general, the
studies in the American literature use a definition of
PF as drainage of/50 ml/24 h of fluid with drain
amylase level of more than three times the serum
amylase level for at least 10 days after surgery
[1,3,20,21,46]. German and Italian papers report a
definition as drain fluid with /10 ml/24 h with drain
amylase level of more than three times the serum
amylase level for 34 days in the postoperative period,
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but many other definitions are present in the surgical
literature [810,18,47]. Moreover, a distinction be-
tween ‘clinical’ and ‘biochemical’ pancreatic leak
should be made, and a ‘clinically relevant fistula’ has
been defined as an anastomotic leak associated with
symptoms [51,56]. Last, but not least, the role of
radiological imaging is debated in defining the pre-
sence of a definite anastomotic leak.
After a Medline search of the last 10 years our
group found 26 different definitions for PF. We
observed that the incidence of anastomotic leakage
ranged from 10% to 28.5% in a group of 242 patients
who underwent pancreatic resection and pancreatico-
enteric anastomosis by our team depending on the PF
definition applied [11].
To try to solve the problem, an international
working group of 37 pancreatic surgeons from high-
volume centres (International Study Group on Pan-
creatic Fistula Definition, ISGPF) reviewed the
literature and their own experience with pancreatic
leakage and determined a common definition of
pancreatic fistula [12].
Definition of pancreatic fistula
The ISGPF defined pancreatic fistula as: ‘an abnor-
mal communication between the pancreatic duct
epithelium and another epithelial surface containing
pancreas-derived, enzyme-rich fluid’ [12].
Diagnosis and grading
The diagnosis of a PF should be based on different
parameters  clinical and biochemical. According to
the ISGPF a pancreatic fistula must be suspected
when ‘the output through an operatively-placed  or
subsequently placed percutaneous drain  of any
measurable volume of drain fluid on or after post-
operative day three with amylase content greater than
three times the upper normal serum value’ [12].
Thus, an accurate evaluation of the daily output
and of the appearance (colour) of each drain, the
measurement of amylase concentration in the drain
fluid, laboratory serum test and monitoring of the
clinical condition of the patient are necessary to
diagnose the development of a PF as early as possible.
In fact, drain fluids could have a colour that ranges
from dark brown (infected fistula) to greenish bilious
fluid to clear ‘spring water’ which seems to be
pancreatic juice; laboratory tests can show an in-
creased C-reactive protein associated with leucocyto-
sis; patients may complain of abdominal pain, delayed
gastric emptying, abdominal distension with altered
bowel function, fever /388C and the evidence of a
sepsis.
Radiological imaging is not necessary in the diag-
nosis of a PF. However, imaging techniques can be of
help as they can show extended intra-abdominal and/T
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or infected collections or the site of the migration of
the drain into an enteric viscus.
Different are criteria used to classify pancreatic
fistulas. Based on the type of secretions they can be
divided into ‘pure’, constituted exclusively of pan-
creatic juice, or ‘mixed’ fistulas in which pancreatic
juice is combined with bile or enteric juice. Moreover,
considering the daily output, pancreatic fistulas can be
classified as low- or high-output fistulas and the cut-
off value of the daily output considered is 200 ml/day.
The ISGPF introduced a grading system for PF
(grades A, B and C) to evaluate the grade of clinical
severity of the PF [12]. Grade A fistula is a ‘transient
fistula’ without any clinical impact. In this case the
patient is well and the use of antibiotics, octreotide or
parenteral nutrition is not necessary. Moreover, a
grade A fistula does not influence the postoperative
course of the patient, who is discharged without delay.
Grade B fistula is a clinically significant PF. It can
be associated with abdominal pain, fever or leucocy-
tosis. Specific treatment is usually used and the
patient is supported by parenteral or enteral nutrition.
The drain should left in place. If abdominal computed
tomography (CT) scan or ultrasound (US) shows
intra-abdominal collections, the re-positioning of
drains must be considered. Grade B fistula usually
leads to prolonged in-hospital stay with increased
costs. Many patients are discharged with drains in
situ , which will be removed in the clinic.
Grade C fistula requires major changes in the
postoperative management of the patient and it is a
life-threatening event. Parenteral or enteral nutrition,
intravenous antibiotics, octreotide administration
and/or intensive care are needed. CT scan can show
the presence of worrisome peripancreatic collections.
Invasive management (open or RX-guided) can be
required. Sepsis can be present and it can lead to
multi-organ failure. A major delay in discharging the
patient is usually required.
Treatment
The treatment of a patient with PF is strictly related to
the clinical conditions. It is primarily conservative and
effective in 8590% of the cases [94103]. In the
remaining cases invasive re-intervention is necessary.
Surgical exploration should be considered for a grade
C fistula, especially when an abdominal abscess or
sepsis  with or without organ dysfunction  is
diagnosed [4,9,63,96,99].
The optimal surgical management in case of
re-operation is based on different options: ‘simple’
wide peripancreatic drainage; a definitive demolition
of the pancreatic anastomosis without a new enteric
anastomosis; a conversion of a type of pancreatico-
enteric anastomosis in another one; a completion
pancreatectomy. However, resecting a few centimetres
of the pancreatic remnant and performing a new
pancreatico-enteric anastomosis is a high-risk proce-
dure with the possibility of new anastomotic failure
with continuing leakage, sepsis and abscess. Some
papers reported a high survival in patients with
peripancreatic abscess after completion pancreatect-
omy. If the general conditions of the patient are poor,
an open drainage procedure should be performed,
delaying the definitive operation [1,3,5,8,9,20
22,63,72,96100].
In patients with a clinically relevant fistula, in the
absence of a sepsis or abdominal abscess, a conserva-
tive management approach is appropriate. It is
important to evaluate intra-abdominal collections:
they must be well drained and a postoperative
replacement of drains can be considered in some
cases [98,99].
Conservative management includes fluid/electrolyte
replacement, suspension of oral intake, nutritional
support by parenteral or enteral nutrition and anti-
biotic administration [4,9,98,99]. In 1979 Klempa et
al. introduced somatostatin and octreotide in the non-
operative management of pancreatic fistula [92].
Octreotide was reported to significantly reduce the
fistula output and to accelerate the healing time even
if other trials did not demonstrate its usefulness.
Thus, the benefit of octreotide administration on the
fistula resolution is unclear and additional studies are
needed.
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